Leuject

Cladribine, the active ingredient in Leuject, is a purine analog antimetabolite presented as a sterile subcutaneous injection for subcutaneous administration. It is used to treat hairy cell leukemia, a rare B‑cell malignancy, and to manage relapsing forms of multiple sclerosis in adult patients.

GNH USA supplies Leuject as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, pharmacies and clinics worldwide under strict quality standards. The company ensures reliable logistics, regulatory compliance and cold‑chain handling where required.

Cladribine is employed in hematologic malignancies and autoimmune neurological disease. - Hairy cell leukemia: induces remission by selectively targeting malignant B‑lymphocytes. - Relapsing‑remitting multiple sclerosis: reduces relapse frequency and slows disability progression through lymphocyte depletion. - Multiple sclerosis (overall): provides disease‑modifying therapy for adults with active disease.

Cladribine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain: mild discomfort or erythema at the injection site. - Lymphopenia: transient reduction in lymphocyte counts. - Fatigue: general tiredness or lack of energy.

Serious or Rare Side Effects: - Severe infections: opportunistic or serious bacterial infections. - Profound lymphopenia: prolonged severe depletion of lymphocytes. - Autoimmune hepatitis: liver inflammation with immune features.

When using Cladribine, several precautions should be observed to minimize risks. - Monitor blood counts: perform regular complete blood count assessments. - Screen for infections: evaluate for active infections before initiating therapy. - Assess liver function: conduct baseline liver enzyme tests and monitor periodically. - Use contraception: advise effective contraception for patients of reproductive potential. - Avoid live vaccines: do not administer live attenuated vaccines during treatment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cladribine can interact with other medicines, influencing its safety or effectiveness.

Major Interactions (Avoid): - Concurrent myelosuppressive agents: increase risk of severe bone‑marrow suppression. - Live vaccines: may cause uncontrolled infection due to immunosuppression. - Antiviral prophylaxis agents (e.g., ganciclovir): may augment toxicity.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., azathioprine): require careful monitoring of immune status. - NSAIDs: may mask signs of infection or increase bleeding risk. - Hormonal contraceptives: no known interaction but monitor efficacy as a precaution.